Meeting
2012 ASCO Annual Meeting
Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.
Authors
Annick Desjardins
Duke University Medical Center, Durham, NC
Annick Desjardins , James J Vredenburgh , Katherine B. Peters , Stevie Threatt , James Emmett Herndon II, John Howard Sampson , Allan H. Friedman , Henry S. Friedman , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00953121
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2095^)
Abstract #
2095^
Poster Bd #
19B
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
First Author: Naotoshi Sugimoto
Poster
2014 ASCO Annual Meeting
A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
First Author: Huichung Tina Ling
Poster
2014 ASCO Annual Meeting
Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
First Author: Eudocia Quant Lee
Poster
2012 ASCO Annual Meeting
Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
First Author: Salvia Sanjay Jain